SkinHealth Systems Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, and an advisory vote on executive compensation, with all proposals recommended by the board. No questions were submitted, and voting results will be disclosed in a Form 8-K filing.
-
Q1 sales declined 6.7% year-over-year to $64.9M, but adjusted EBITDA rose 17% to $8.5M, exceeding guidance. Full-year revenue outlook was lowered to $280M-$295M due to ongoing device demand softness, while EBITDA guidance was maintained, reflecting margin strength and operational discipline.
Fiscal Year 2025
-
Margins and profitability improved in Q4 and full-year 2025, with recurring consumables revenue showing resilience despite macro headwinds. 2026 is set as an execution year, with growth expected to resume in 2027 as operational initiatives and innovation take effect.
-
Q3 net sales declined 10.3% year-over-year to $70.7M, with device sales down 24.6% and consumables down 2.6%, but adjusted EBITDA rose 11% to $8.9M. Full-year guidance was raised, and the company is focusing on core consumables, innovation, and operational discipline.
-
Q2 2025 results exceeded expectations with strong consumables growth, margin expansion, and disciplined cost control. Device sales remain pressured by macro headwinds, but recurring revenue and innovation drive confidence in long-term growth.
-
Q1 2025 results exceeded expectations with strong consumables growth and improved profitability, despite macroeconomic and tariff pressures. Strategic initiatives, innovation, and a shift to a distributor model in China are positioning the business for sustainable growth.
Fiscal Year 2024
-
Full-year revenue and adjusted EBITDA exceeded guidance, driven by strong consumable sales and cost reductions, despite a sharp decline in equipment sales and ongoing macroeconomic headwinds. The company is transitioning to a distributor model in China and expects continued pressure on device sales in 2025.
-
Q3 revenue exceeded guidance midpoint but fell 19% year-over-year due to weak device sales, especially internationally, while consumables grew 10%. Adjusted gross margin reached 69.5%, and cost controls improved profitability. Full-year guidance reflects continued international headwinds and a focus on margin expansion in 2025.
-
Q2 2024 saw a 23% revenue decline, driven by weak equipment sales and macro headwinds, but consumables grew 7%. Cost reductions and new sales strategies are underway, with positive Adjusted EBITDA expected in Q4 and a strong cash position maintained.